Abbreviations: BOS, bronchiolitis obliterans syndrome; CLAD, chronic lung allograft dysfunction; FDG, fluorodeoxyglucose; FEV 1 , forced expiratory volume in 1 second; FVC, forced vital capacity; Ig, immunoglobulins; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; LTx, lung transplantation; OB, obliterative bronchiolitis; RAS, restrictive allograft syndrome; SSLTx, sequential single lung transplantation; SUVmax, maximum standardized uptake value; TLC, total lung capacity. Pirfenidone may attenuate the decline of pulmonary function in restrictive allograft syndrome (RAS) after lung transplantation. We retrospectively assessed all lung transplant recipients with RAS who were treated with pirfenidone for at least 3 months (n = 11) in our lung transplant center and report on their long-term outcomes following initiation of pirfenidone. Main outcome parameters included evolution of pulmonary function and overall survival. Pirfenidone appears to attenuate the decline in forced vital capacity and forced expiratory volume in 1 second. Notably, 3 patients were bridged to redo-transplantation with pirfenidone for 11 (5-12) months and are currently alive, while 3 other patients demonstrate long-term stabilization of pulmonary function after 26.6 (range 18.4-46.6) months of treatment. Median overall 3-year survival after RAS diagnosis was 54.5%. Subjective intolerance, mainly anorexia and nausea, necessitating pirfenidone dose de-escalation in 55% of patients, as well as calcineurin dose increase requirements with about 20% are important complications during pirfenidone treatment after lung transplantation. Our findings provide further evidence that pirfenidone appears to be safe and may attenuate the rate of decline in lung function in patients with RAS, but the actual clinical benefit cannot be assessed in the context of this study design and requires further investigation in a larger randomized trial.
Pirfenidone may attenuate the decline of pulmonary function in restrictive allograft syndrome (RAS) after lung transplantation. We retrospectively assessed all lung transplant recipients with RAS who were treated with pirfenidone for at least 3 months (n = 11) in our lung transplant center and report on their long-term outcomes following initiation of pirfenidone. Main outcome parameters included evolution of pulmonary function and overall survival. Pirfenidone appears to attenuate the decline in forced vital capacity and forced expiratory volume in 1 second. Notably, 3 patients were bridged to redo-transplantation with pirfenidone for 11 (5) (6) (7) (8) (9) (10) (11) (12) months and are currently alive, while 3 other patients demonstrate long-term stabilization of pulmonary function after 26.6 (range 18.4-46.6) months of treatment. Median overall 3-year survival after RAS diagnosis was 54.5%. Subjective intolerance, mainly anorexia and nausea, necessitating pirfenidone dose de-escalation in 55% of patients, as well as calcineurin dose increase requirements with about 20% are important complications during pirfenidone treatment after lung transplantation. Our findings provide further evidence that pirfenidone appears to be safe and may attenuate the rate of decline in lung function in patients with RAS, but the actual clinical benefit cannot be assessed in the context of this study design and requires further investigation in a larger randomized trial.
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| INTRODUC TI ON
Restrictive allograft syndrome (RAS) was recently identified as a rare and distinct novel phenotype of chronic lung allograft dysfunction (CLAD) following lung transplantation (LTx), besides bronchiolitis obliterans syndrome (BOS). [1] [2] [3] [4] RAS is characterized by restrictive pulmonary physiology and persistent pleuroparenchymal abnormalities, such as peripheral ground-glass opacities, consolidation, traction bronchiectasis, architectural distortion, and (sub)pleural thickening on chest computed tomography (CT) scan. [1] [2] [3] [5] [6] [7] [8] On histology, obliterative bronchiolitis (OB), together with pleuroparenchymal fibroelastosis, nonspecific interstitial pneumonia, or other interstitial and fibrotic changes can be seen, [9] [10] [11] which is associated with marked local T and B cell accumulation. 12, 13 Importantly, RAS carries an unfavorable prognosis with a median survival of 1-1.5 years after disease onset. 1, 2, 14 Adequate treatment options are currently lacking, except perhaps retransplantation in well-selected cases. 15 RAS may, however, redevelop in some patients after redo-transplantation.
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Therefore, pharmacological therapy for RAS is an unmet medical need and novel treatment options for RAS are urgently needed.
Pirfenidone, which has anti-inflammatory and antifibrotic properties and is approved for treatment of idiopathic pulmonary fibrosis (IPF), may be such a drug. 16 We previously reported on a first RAS patient treated with pirfenidone, demonstrating relative stabilization of spirometry and of specific CT features after 3 months (subpleural consolidations and ground-glass opacities). 17 Interestingly, stabilization of pulmonary function with pirfenidone was later also shown in a case of BOS. 18 Moreover, increased 18 F-fluorodeoxyglucose (FDG) uptake in fibrotic subpleural regions at RAS diagnosis was seen, suggestive of active local inflammation and/or parenchymatous remodeling, similar to what has been described in IPF. 19, 20 These findings were recently confirmed by our group in a retrospective study comparing LTx recipients with RAS, BOS, or stable condition, demonstrating a significantly higher pulmonary 18 F-FDG uptake in RAS vs BOS or stable patients. Moreover, a possible prognostic role for 18 F-FDG positron emission tomography (PET)/CT regarding subsequent pulmonary function and graft survival in RAS was recently demonstrated.
21
We hypothesized a beneficial effect on the evolution of pulmonary function during treatment with pirfenidone in RAS, as well as a possible attenuation of local 18 F-FDG uptake in RAS, which we sought to confirm in several other RAS patients, prospectively treated with pirfenidone since 2013 in our center, for which results are reported in the current case-series.
| MATERIAL S AND ME THODS

| Study design and population
Eligible LTx recipients diagnosed with RAS as of 2013 (ie, following our reported first case, 17) were prospectively treated with off-label pirfenidone, following prior approval by the local Ethics
Committee (S57845/ML9518) and written informed consent. Also, patients consented to access their clinical and biobanked data for research (S51577/ML5629). Patients were excluded for the current analysis if they had received pirfenidone for less than 3 months (n = 6 currently, average duration 1.9 months), based on the fact that it may take several weeks to demonstrate clinical beneficial effects of pirfenidone as was previously demonstrated in IPF, in which the treatment effect of pirfenidone regarding forced vital capacity (FVC) only became evident by weeks 12-24 compared to placebo.
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Aside from eligible RAS patients initiated on pirfenidone, some (n = 12) other progressive RAS cases were diagnosed in the time period 2013-2017: n = 3 single lung transplant recipients (all died of RAS at median 14 months after RAS onset), n = 2 combined organ transplant recipients (heart-lung transplant, lung + liver transplant;
both died of RAS also at median 14 months after onset), n = 3 sequential single (bilateral) lung transplant (SSLTx) recipients with acute onset and very rapid progressive RAS with survival <3 months after diagnosis (all died of RAS at median 1.5 months after onset), n = 4
SSLTx recipients with progressive deterioration (thus comparable to the cohort on pirfenidone; all died of RAS at median of 10 months after onset). The latter patients were not initiated on off-label pirfenidone treatment because of refusal of consent, ethical (only approval for SSLTx), or medical reasons (ie, rapid decline to death after onset, palliative situation; or renal insufficiency or severe hepatic failure as indicated in the summary of product characteristics for pirfenidone).
| Assessment of pulmonary function, radiology, CLAD status, and mortality
Spirometry (Master screen; Jaeger, Hoechberg, Germany) [22] [23] [24] was assessed at baseline (best postoperative value), 12/6/3/2/1 months prior to start of pirfenidone, at start of pirfenidone; and at 1/2/3/6/9/12 months after start of pirfenidone; as well as at later time points on condition that patients were still alive without redotransplantation at that time. Per follow-up protocol, total lung capacity (TLC) (and diffusing capacity for carbon monoxide) measurements after LTx were only systematically performed on an annual basis in our center, or exceptionally for specific indications (ie, at RAS diagnosis, at start of pirfenidone, and so on), but not on a regular basis (ie, for instance, every 3 months, unlike spirometry), because of healthcare budget constraints in costs and personnel. Chest CT and 18 F -FDG PET/CT imaging were performed as previously described. 7, 13, 21, 25 CLAD was diagnosed as a persistent decline in forced expira- 
| Statistical analysis
All analyses were performed using GraphPad Prism 5a software (San 
| RE SULTS
| Study population and patient characteristics
Patients' characteristics are summarized in Table 1 was needed to maintain stable therapeutic (6-8 µg/L) trough levels: 7.8 ± 1.7 (at start) vs 6.4 ± 1.3 µg/L (after 3 months) (P = .027).
A similar trend (+20% dose increase) was seen in 1 patient on cyclosporine. No other significant drug interactions, either phototoxicity or development of hepatic impairment, were noticed in any of the patients during pirfenidone treatment. 
| Evolution of pulmonary function with pirfenidone
TA B L E 1 (Continued)
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| Evolution of lung allograft imaging with pirfenidone
Routine chest CT at standardized time intervals following initiation of pirfenidone was not possible; however, most patients had repeat chest CT scans performed sometime during their subsequent follow-up, as per routine annual posttransplant protocol.
Representative images of chest CT scan prior to start of pirfenidone, as well as of the last available CT scan during treatment of pirfenidone, are given in Figure 3 . Because of the variable time interval between start and last CT scan, assessment of the evolution of parenchymal infiltrates is difficult, but significant resolution of subpleural infiltrates and pleural thickening was not present.
As per study protocol, most included RAS patients (n = 10/11, CT are given in Figure 4 (1 patient had no PET/CT fusion images available after 3 months, only attenuation-corrected PET images for SUVmax calculation).
| Overall survival and graft loss in RAS with pirfenidone
During follow-up, n = 5/11 patients (45%) died, on average 14 
| D ISCUSS I ON
The dismal prognosis of RAS and the lack of efficacious medical therapeutic options (except perhaps lung redo-transplantation in selected cases) provide a strong rationale for a novel treatment approach of this devastating condition. As such, the pathophysiologic mechanisms leading to tissue fibrosis in the lung allograft in RAS are thought to be, at last partially, similar to those in IPF. 2, 3, [9] [10] [11] Therefore, antifibrotic therapies may contribute to maintenance of allograft function and improved outcomes in RAS.
In the current case series, we report on the evolution of pulmonary function during treatment with pirfenidone in 11 patients with RAS. Our findings provide further evidence that pirfenidone appears to be safe and may attenuate the rate of decline in lung function (FVC and FEV 1 ) in patients with RAS, confirming our findings in a prior case. 17 Notably, 3 patients were bridged to redotransplantation with pirfenidone for 11 (5) (6) (7) (8) (9) (10) (11) (12) and tumor necrosis factor-α (TNF-α), important mediators of fibrosis and inflammation. 27 Consequently, pirfenidone reduces fibroblast proliferation and collagen synthesis, which is thought to attenuate tissue fibrosis and subsequent organ dysfunction. Interestingly, pirfenidone demonstrates various immune-modulating effects, including inhibition of the production of pro-fibrotic mediators (eg, IL-12, IL-18, and fibroblast growth factor). Moreover, it also exhibits antioxidant properties (by scavenging reactive oxygen species and preventing lipid peroxidation), has inhibitory effects on dendritic cells, and may attenuate lung allograft rejection, as described in a murine lung transplant model, 28,29 murine trachea transplant model, 30 and rat lung transplant model. 31 Interestingly, pirfenidone was also shown to ameliorate murine chronic graft-vs-host disease (GvHD) through inhibition of macrophage infiltration and TGF-β production. 32 Since pulmonary GvHD is characterized by small airways disease, obliteration, and sometimes concurrent (pleuro-) parenchymal fibrosis/fibro-elastosis (similar to RAS after LTx), patients with pulmonary GvHD may theoretically possibly also benefit from pirfenidone treatment, as was recently demonstrated with another antifibrotic drug-nintedanib-in 2 patients with fibrotic lung disease after allogeneic hematopoietic stem cell transplantation.
33
In IPF, pirfenidone has been shown to reduce disease progression, evidenced by a decreased decline in FVC and improvement of clinically relevant outcomes, such as progression-free survival, all-cause mortality, IPF-related mortality, and IPF exacerbations. nicely described by Sato et al. 2 In our cohort, pirfenidone was only initiated in "progressive" RAS patients, ie, with further decline in pulmonary function after disease onset. This likely explains why n = 7/11 patients were initiated within 6 months after RAS diagnosis (early progressive), and (only) 4/11 patients were initiated on pirfenidone later than 6 months after RAS diagnosis (late progressive). Moreover, given the off-label treatment, individual
Institutional Ethical Review Board approval for each patient and F I G U R E 3 Chest CT images before vs during pirfenidone treatment. CT before vs after initiation of pirfenidone demonstrates peribronchiolar and/or subpleural ground-glass opacities and/or consolidations, inter-and intralobular septal thickening, and/or traction bronchiectasis, with variable distribution in the different patients, compatible with RAS. CT, computed tomography; RAS, restrictive allograft syndrome acquisition of the drug from InterMune/Roche caused a delay in initiation of this treatment of at least 3-4 weeks on average. These factors thus resulted in a median time to start of several months after RAS diagnosis. However, perhaps earlier initiation of treatment after RAS onset (ie, in case of "early stage disease") may even prove to be more efficacious, which needs to be further studied.
Other obvious drawbacks to the current study are the low number of patients, lack of true "controls," and retrospective design. Also, a formal and uniform RAS definition is still lacking, but this is cur- equally valuable for all RAS cases should preferably be validated in a formal randomized trial. Yet given the extremely low incidence of this "orphan" disease (ie, ≈70% of CLAD is attributable to BOS and only 30% to RAS), this will require a multicenter setup. Also, side effects and drug interactions in multidrug-treated lung transplant recipients may pose a significant problem in this trial, possibly leading to high dropout numbers.
In conclusion, our findings provide further evidence that pirfenidone appears to be safe and may attenuate the rate of decline in lung function in RAS, but the actual clinical benefit cannot be assessed in the context of this study design and absolutely requires further investigation in a larger randomized trial.
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